- Home
- ED vs ONC Comparison
ED vs ONC Comparison
Compare ED & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ED
- ONC
- Stock Information
- Founded
- ED 1884
- ONC 2010
- Country
- ED United States
- ONC Switzerland
- Employees
- ED N/A
- ONC N/A
- Industry
- ED Power Generation
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- ED Utilities
- ONC Health Care
- Exchange
- ED Nasdaq
- ONC Nasdaq
- Market Cap
- ED 36.1B
- ONC 34.8B
- IPO Year
- ED N/A
- ONC N/A
- Fundamental
- Price
- ED $99.96
- ONC $310.06
- Analyst Decision
- ED Hold
- ONC Strong Buy
- Analyst Count
- ED 12
- ONC 10
- Target Price
- ED $104.83
- ONC $350.00
- AVG Volume (30 Days)
- ED 1.6M
- ONC 227.5K
- Earning Date
- ED 11-06-2025
- ONC 11-06-2025
- Dividend Yield
- ED 3.40%
- ONC N/A
- EPS Growth
- ED 7.14
- ONC N/A
- EPS
- ED 5.50
- ONC N/A
- Revenue
- ED $16,154,000,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- ED $9.96
- ONC $887.89
- Revenue Next Year
- ED $3.91
- ONC $22.45
- P/E Ratio
- ED $18.18
- ONC N/A
- Revenue Growth
- ED 9.07
- ONC 47.33
- 52 Week Low
- ED $87.28
- ONC $170.99
- 52 Week High
- ED $114.87
- ONC $355.30
- Technical
- Relative Strength Index (RSI)
- ED 48.32
- ONC 41.01
- Support Level
- ED $100.43
- ONC $306.00
- Resistance Level
- ED $103.10
- ONC $319.57
- Average True Range (ATR)
- ED 1.62
- ONC 8.04
- MACD
- ED -0.07
- ONC -2.94
- Stochastic Oscillator
- ED 33.12
- ONC 8.64
About ED Consolidated Edison Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York - including New York City and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.